EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer

Haonan Liu, Di Pan, Zhiyuan Yao, Hongmei Wang, Yuqi Li, Xiaobing Qin, Pengfei Qu, Juanjuan Tang, Zhengxiang Han

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Haonan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer (PC). METHODS: Data of 52 patients with advanced PC who were treated in the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) between August 2019 and March 2023 were retrospectively analyzed. According to the treatment regimen, patients were divided into two groups, including 27 patients in the chemotherapy group (AG regimen) and 25 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitors). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were compared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify independent risk factors influencing prognosis. RESULTS: The median OS and PFS in the combined treatment group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.9 months, P = 0.005; PFS, 5.6 vs. 4.4 months, P = 0.003). There was no significant difference in ORR between the two groups (32.0 % vs. 25.9 %, P = 0.629), and DCR in the combined treatment group was significantly better than that in the chemotherapy group (84.0 % vs. 59.3 %, P = 0.049). Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction-related deaths occurred. CONCLUSION: Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitors exhibited to have a higher efficacy for the first-line treatment of advanced PC, and the adverse reactions were also controllable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsGemcitabineAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidinePaclitaxelAlbuminsIndolesQuinolinesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorTreatment Outcome

Stichwörter der Autor:innen

AnlotinibChemotherapyEfficacyPD-1 inhibitorPancreatic cancerSafety

Substanzen

anlotinibGemcitabineDeoxycytidinePaclitaxelAlbuminsIndolesQuinolines130-nm albumin-bound paclitaxelImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: tm350347@163.com.
  • Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: cnhzxyq@163.com.

Zitieren

APA

Liu, H., Pan, D., Yao, Z., Wang, H., Li, Y., Qin, X., Qu, P., Tang, J., & Han, Z. (2024). Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112635

Vancouver

Liu H, Pan D, Yao Z, Wang H, Li Y, Qin X, et al. Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112635

BibTeX
@article{Liu2024,
  author = {Liu, Haonan and Pan, Di and Yao, Zhiyuan and Wang, Hongmei and Li, Yuqi and Qin, Xiaobing and Qu, Pengfei and Tang, Juanjuan and Han, Zhengxiang},
  title = {Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112635}
}
Kostenlos starten →